Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

Abstract Background Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor with substantial clinical activities in patients with NRAS-mutant melanoma. This phase I study evaluated the safety and preliminary efficacy of tunlametinib plus vemurafenib in patients with advanced BRAF V600-mutan...

Full description

Bibliographic Details

Published in:	Experimental Hematology & Oncology
Main Authors:	Yuankai Shi, Xiaohong Han, Qian Zhao, YuLong Zheng, Jianhua Chen, Xinmin Yu, Jian Fang, Yutao Liu, Dingzhi Huang, Tianshu Liu, Hong Shen, Suxia Luo, Hongsheng Yu, Yu Cao, Xi Zhang, Pei Hu
Format:	Article
Language:	English
Published:	BMC 2024-06-01
Subjects:	Tunlametinib MEK inhibitor Vemurafenib BRAF Non-small cell lung cancer Colorectal cancer
Online Access:	https://doi.org/10.1186/s40164-024-00528-0